FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 4605 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses. PMID 39018512 · Neurology · 2024-Aug-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. PMID 38772835 · Vaccine · 2024-Aug-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Community acceptance of a novel malaria intervention, Attractive Targeted Sugar Baits, in the Zambia phase III trial. PMID 39129018 · Malar J · 2024-Aug-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. PMID 38833659 · J Clin Oncol · 2024-Aug-10 The study is a randomized Phase III oncology trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) or related analyses (Kaplan-Meier, HR). The primary endpoint (complete response rate) and secondary endpoint (proportion free of nausea) are categorical proportions, not time-to-event outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. PMID 38828955 · N Engl J Med · 2024-Aug-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. PMID 38828945 · N Engl J Med · 2024-Aug-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. PMID 39107270 · Nat Commun · 2024-Aug-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. PMID 39056349 · J Am Heart Assoc · 2024-Aug-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Acute Declines in Estimated Glomerular Filtration Rate in Patients Treated With Benazepril and Hydrochlorothiazide Versus Amlodipine and Risk of Cardiovascular Outcomes. PMID 39056339 · J Am Heart Assoc · 2024-Aug-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. PMID 38762797 · JAMA · 2024-Aug-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. PMID 39067461 · Lancet · 2024-Aug-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. PMID 39033766 · Lancet · 2024-Aug-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy. PMID 39095808 · Cardiovasc Diabetol · 2024-Aug-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data. PMID 40788226 · J Acquir Immune Defic Syndr · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain: A Phase 3 Randomized Clinical Trial. PMID 39158916 · JAMA Netw Open · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Promoting Resilience in Stress Management for Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. PMID 39158914 · JAMA Netw Open · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial. PMID 39150711 · JAMA Netw Open · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial. PMID 39106066 · JAMA Netw Open · 2024-Aug-01 The study is a Phase 3 randomized trial with a drug intervention in oncology, but it does not meet the requirement for a primary or key secondary time-to-event efficacy endpoint. The primary endpoint (complete response) is a binary categorical outcome, not a time-to-event measure like OS, PFS, or TTP analyzed via Kaplan-Meier or Hazard Ratio. The study focuses on preventing chemotherapy-induced nausea and vomiting, which is a supportive care endpoint, not a direct measure of tumor-related efficacy. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates: A Randomized Clinical Trial. PMID 39088218 · JAMA Netw Open · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial. PMID 38900416 · JAMA Otolaryngol Head Neck Surg · 2024-Aug-01 The study is a Phase III randomized controlled trial with a drug/radiopharmaceutical intervention and reports primary results, but it is not an oncology study (it addresses primary hyperparathyroidism, a non-malignant endocrine condition) and its primary endpoint is a dichotomous outcome (successful minimally invasive parathyroidectomy combined with normocalcemia), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials. PMID 38865146 · JAMA Dermatol · 2024-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials. PMID 38825359 · J Rheumatol · 2024-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. PMID 38717861 · Blood · 2024-Aug-01 This is a secondary analysis report of a Phase 3 randomized trial. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results, it is excluded because the primary focus and presented results are on a quality-of-life endpoint, not the required time-to-event efficacy endpoint (e.g., OS, PFS). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07: a randomized controlled trial. PMID 38716987 · Int J Surg · 2024-Aug-01 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. PMID 38691387 · JAMA Psychiatry · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a single-pill versus free combination of perindopril/indapamide/amlodipine: a multicenter, randomized, double-blind study in Chinese patients with hypertension. PMID 38660708 · J Hypertens · 2024-Aug-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder. PMID 38657773 · J Affect Disord · 2024-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. PMID 38581694 · Cancer · 2024-Aug-01 The trial meets criteria for oncology, human, randomized, phase 3, and original result. However, it is ineligible because (1) the intervention is non-drug-only (radiation therapy only) and (2) the primary endpoint is not a time-to-event efficacy endpoint; it is a pain response rate at a fixed time point. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis. PMID 39143826 · Mult Scler · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL). PMID 39137167 · PLoS Med · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials. PMID 39106052 · Expert Rev Respir Med · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial. PMID 39008999 · Lancet HIV · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. PMID 38978354 · Ann Clin Transl Neurol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. PMID 38954874 · Eur Neuropsychopharmacol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. PMID 38954317 · CNS Drugs · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF. PMID 38932589 · Eur J Heart Fail · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia. PMID 38904165 · Eur J Contracept Reprod Health Care · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| No add-on therapeutic benefit of at-home anodal tDCS of the primary motor cortex to mindfulness meditation in patients with fibromyalgia. PMID 38901112 · Clin Neurophysiol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. PMID 38885672 · Lancet Haematol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. PMID 38880118 · Lancet Neurol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study. PMID 38878794 · Lancet Microbe · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. PMID 38878121 · Adv Ther · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. PMID 38867615 · Br J Haematol · 2024-Aug The record describes a Phase III randomized trial in follicular lymphoma with drug interventions, but the primary analysis is immunogenicity of COVID-19 vaccines (antibody and T-cell responses), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor Kaplan-Meier or HR for such endpoints. Therefore, it does not meet the time-to-event efficacy requirement. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients. PMID 38851462 · Int J Antimicrob Agents · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. PMID 38844797 · Nat Med · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. PMID 38844682 · Clin Rheumatol · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221. PMID 38814343 · Cancer Chemother Pharmacol · 2024-Aug The record describes a secondary/biomarker analysis from a Phase III randomized trial in early-stage breast cancer. While it meets criteria for oncology, human, randomized, Phase III, and drug intervention, the primary endpoint is not a time-to-event efficacy outcome. The study investigates the association between pre-treatment amino acid levels and the risk/severity of chemotherapy-induced peripheral neuropathy, which is a safety/toxicity endpoint, not a key efficacy endpoint like OS, PFS, or DFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies. PMID 38797892 · Clin Pharmacol Ther · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early versus late follicular phase ovarian stimulation: a randomized controlled trial. PMID 38763121 · Reprod Biomed Online · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. PMID 38757725 · Diabetes Obes Metab · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |